Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report

Chronic inflammatory demyelinating polyneuropathy (CIDP) is a neuropathic condition affecting peripheral nerves and nerve roots. It is acquired and mediated by the immune system, typically presenting with recurring or progressively worsening symmetrical weakness in both proximal and distal muscle groups. Clinically, CIDP is divided into two categories: “typical” and “atypical” cases. Typical CIDP manifests as a symmetrical polyneuropathy, equally impacting both proximal and distal muscles. In contrast, atypical CIDP includes conditions like ‘distal acquired demyelinating symmetric’ (DADS) and multifocal acquired demyelinating sensory and motor neuropathy (MADSAM), also known as Lewis-Sumner syndrome (LSS). DADS is characterized by a symmetrical, length-dependent sensory or sensorimotor neuropathy, often associated with an IgM paraprotein and significantly increased distal motor latencies. While these features resemble demyelinating neuropathy with antibodies against myelin-associated glycoprotein (MAG), anti-MAG neuropathy is excluded from CIDP according to EFNS/PNS criteria due to the presence of specific antibody presence and distinct treatment responses. LSS exhibits a multifocal distribution; a key electrophysiological feature is a conduction block. Additionally, pure motor and sensory CIDP variants have been documented, with some cases restricted to sensory nerve roots, referred to as chronic immune sensory polyradiculopathy. CIDP is diagnosed based on electrodiagnostic or pathological evidence of demyelination and a positive response to immunomodulatory therapies. The most common subtype is typical CIDP, accounting for at least 50 to 60 percent of all cases. Panzyga® (Immune Globulin Intravenous [Human] – 10 percent Liquid Preparation) treats adults with CIDP, a neurological disorder affecting the peripheral nerves.
• The estimated annual incidence of CIDP in the USA is 8.9 cases per 100,000 individuals. This condition is more commonly observed in male patients, with a male-to-female ratio of 2:1, and it tends to be more prevalent among older individuals.

Thelansis’s “Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033″ covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

KOLs insights of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.
Read more: Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033
Tags: Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) market outlook, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) competitive landscape, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) market forecast, Thelansis, Primary market research, KOL insights, Competitive Intelligence (CI)